Viking Therapeutics Initiates Pivotal Phase 3 Trial: Here's Why Investors Have Reason for Optimism After a Disappointing Phase 2
Key PointsViking is launching phase 3 trials for oral VK2735 after mixed phase 2 results.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.